drugset / Trial / NCT01725620

Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®

NCT01725620

Phase 1 Completed 48 enrolled LG Life Sciences
RandomizedCrossoverDouble-blindTreatment

Summary

To compare the pharmacokinetic characteristic of LBEC0101 25mg with active comparator, Enbrel® 25mg.

Timeline

Start
2012-11
Primary completion
2013-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous
Subject LBEC0101 Protein / enzyme biologic 25 mg Subcutaneous

Indications

No indication recorded.